Nov 10, 2026 4:05 pm EST Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 09, 2026 9:00 am EST Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
Nov 03, 2026 9:00 am EST Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10
Oct 05, 2026 9:00 am EDT Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
Sep 17, 2026 8:30 am EDT Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
Aug 24, 2026 9:25 am EDT Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
Aug 13, 2026 4:05 pm EDT Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 10, 2026 8:30 am EDT Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13
Jul 30, 2026 9:30 am EDT Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
Jul 29, 2026 10:05 am EDT The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy